Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Eskens, Bart J M ^a   Zuurbier, Coert J ^b   Van Haare, Judith ^a   Vink, Hans ^a   Van Teeffelen, Jurgen W G E ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

db db; Diabetes; Glycocalyx; Metformin

Indexed keywords

DEXTRAN; DRINKING WATER; FLUORESCEIN; GLUCOSE; METFORMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CAROTID ARTERY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG EFFECT; ERYTHROCYTE; GLUCOSE BLOOD LEVEL; GLYCOCALYX; HEART; HEART WEIGHT; KIDNEY; KIDNEY MASS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA VOLUME; URINALYSIS; URINE;

ANIMALS; BLOOD GLUCOSE; CAPILLARY PERMEABILITY; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GLYCOCALYX; HEMODYNAMICS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE; MICE, INBRED C57BL; TIME FACTORS; URINATION; WATER-ELECTROLYTE BALANCE;

EID: 84889030469     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-175     Document Type: Article

References (53)

1. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996, 334:574-579. 10.1056/NEJM199602293340906, 8569826.
2. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002, 137:25-33. 10.7326/0003-4819-137-1-200207020-00009, 12093242.
3. Matthaei S, Reibold JP, Hamann A, Benecke H, Haring HU, Greten H, Klein HH. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 1993, 133:304-311. 10.1210/en.133.1.304, 8391425.
4. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WGT, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004, 279:43940-43951. 10.1074/jbc.M404421200, 15265871.
5. UK prospective diabetes study (UKPDS) group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet 1998, 352:854-865. UK prospective diabetes study (UKPDS) group.
6. Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 2008, 22:215-224. 10.1007/s10557-008-6092-0, 18288595.
7. Wiernsperger N. 50 years later: is metformin a vascular drug with antidiabetic properties?. Brit J Diab Vasc Dis 2007, 7:204-210.
8. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005, 258:250-256. 10.1111/j.1365-2796.2005.01531.x, 16115299.
9. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001, 37:1344-1350. 10.1016/S0735-1097(01)01129-9, 11300445.
10. De Jager J, Kooy A, Lehert P, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005, 257:100-109. 10.1111/j.1365-2796.2004.01420.x, 15606381.
11. Katakam PV, Ujhelyi MR, Hoenig M, Miller AW. Metformin improves vascular function in insulin-resistant rats. Hypertension 2000, 35:108-112. 10.1161/01.HYP.35.1.108, 10642283.
12. Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther 2000, 2:259-272. 10.1089/15209150050025230, 11469268.
13. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol 2005, 16:507-511. 10.1097/01.mol.0000181325.08926.9c, 16148534.
14. Van Teeffelen JW, Brands J, Stroes ES, Vink H. Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med 2007, 17:101-105. 10.1016/j.tcm.2007.02.002, 17418372.
15. Lipowsky HH. The endothelial glycocalyx as a barrier to leukocyte adhesion and its mediation by extracellular proteases. Ann Biomed Eng 2012, 40:840-848. 10.1007/s10439-011-0427-x, 3306510, 21984514.
16. Mochizuki S, Vink H, Hiramatsu O, Kajita T, Shigeto F, Spaan JA, Kajiya F. Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am J Physiol Heart Circ Physiol 2003, 285:H722-726.
17. Constantinescu AA, Vink H, Spaan JA. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol 2003, 23:1541-1547. 10.1161/01.ATV.0000085630.24353.3D, 12855481.
18. Mulivor AW, Lipowsky HH. Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol 2002, 283:H1282-1291.
19. van den Berg BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res 2003, 92:592-594. 10.1161/01.RES.0000065917.53950.75, 12637366.
20. Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol 2010, 105:687-701. 10.1007/s00395-010-0118-z, 20859744.
21. Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, Meijers JC, Holleman F, Hoekstra JB, Vink H, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006, 55:480-486. 10.2337/diabetes.55.02.06.db05-1103, 16443784.
22. Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JB, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006, 55:1127-1132. 10.2337/diabetes.55.04.06.db05-1619, 16567538.
23. Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ES, Vink H. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010, 53:2646-2655. 10.1007/s00125-010-1910-x, 2974920, 20865240.
24. Zuurbier CJ, Demirci C, Koeman A, Vink H, Ince C. Short-term hyperglycemia increases endothelial glycocalyx permeability and acutely decreases lineal density of capillaries with flowing red blood cells. J Appl Physiol 2005, 99:1471-1476. 10.1152/japplphysiol.00436.2005, 16024521.
25. Vanteeffelen JW, Brands J, Janssen BJ, Vink H. Effect of acute hyaluronidase treatment of the glycocalyx on tracer-based whole body vascular volume estimates in mice. J Appl Physiol 2013, 114:1132-1140. 10.1152/japplphysiol.00842.2012, 23449940.
26. VanTeeffelen JW, Brands J, Jansen C, Spaan JA, Vink H. Heparin impairs glycocalyx barrier properties and attenuates shear dependent vasodilation in mice. Hypertension 2007, 50:261-267. 10.1161/HYPERTENSIONAHA.107.089250, 17452501.
27. Meuwese MC, Broekhuizen LN, Kuikhoven M, Heeneman S, Lutgens E, Gijbels MJ, Nieuwdorp M, Peutz CJ, Stroes ES, Vink H, van den Berg BM. Endothelial surface layer degradation by chronic hyaluronidase infusion induces proteinuria in apolipoprotein E-deficient mice. PloS one 2010, 5:e14262. 10.1371/journal.pone.0014262, 2999536, 21170388.
28. Vink H, Duling BR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 1996, 79:581-589. 10.1161/01.RES.79.3.581, 8781491.
29. de Aguiar LG K, Laflor CM, Bahia L, Villela NR, Wiernsperger N, Bottino DA, Bouskela E. Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome. Diabet Med 2007, 24:272-279. 10.1111/j.1464-5491.2007.02082.x, 17263761.
30. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovasc Diabetol 2012, 11:61. 10.1186/1475-2840-11-61, 3471007, 22676459.
31. de Jager J, Kooy A, Schalkwijk C, van der Kolk J, Lehert P, Bets D, Wulffele MG, Donker AJ, Stehouwer CD. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med 2013, doi: 10.1111/joim.12128.
32. Eriksson L, Erdogdu O, Nystrom T, Zhang Q, Sjoholm A. Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells. Cardiovas Diab 2012, 11:27.
33. Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, Morii T, Narita T, Kakei M, Ito S. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J 2005, 52:427-433. 10.1507/endocrj.52.427, 16127210.
34. Tang T, Reed MJ. Exercise adds to metformin and acarbose efficacy in db/db mice. Metabolism 2001, 50:1049-1053. 10.1053/meta.2001.25596, 11555837.
35. Verma S, Bhanot S, McNeill JH. Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther 1994, 271:1334-1337.
36. Vink H, Duling BR. Capillary endothelial surface layer selectively reduces plasma solute distribution volume. Am J Physiol Heart Circ Physiol 2000, 278:H285-289.
37. Henry CB, Duling BR. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol 1999, 277:H508-514.
38. VanTeeffelen JW, Constantinescu AA, Brands J, Spaan JA, Vink H. Bradykinin- and sodium nitroprusside-induced increases in capillary tube haematocrit in mouse cremaster muscle are associated with impaired glycocalyx barrier properties. J Physiol 2008, 586:3207-3218. 10.1113/jphysiol.2008.152975, 2538786, 18450777.
39. van Haaren PM, VanBavel E, Vink H, Spaan JA. Localization of the permeability barrier to solutes in isolated arteries by confocal microscopy. Am J Physiol 2003, 285:H2848-2856.
40. Gao L, Lipowsky HH. Composition of the endothelial glycocalyx and its relation to its thickness and diffusion of small solutes. Microvasc Res 2010, 80:394-401. 10.1016/j.mvr.2010.06.005, 2962421, 20600162.
41. Cabrales P, Vazquez BY, Tsai AG, Intaglietta M. Microvascular and capillary perfusion following glycocalyx degradation. J Appl Physiol 2007, 102:2251-2259. 10.1152/japplphysiol.01155.2006, 17347383.
42. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070. 10.1161/CIRCRESAHA.110.223545, 2996922, 21030723.
43. Wiernsperger NF. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab 2003, 29:579-585. 10.1016/S1262-3636(07)70072-1, 14707886.
44. Vink H, Constantinescu AA, Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer : implications for platelet-endothelial cell adhesion. Circulation 2000, 101:1500-1502. 10.1161/01.CIR.101.13.1500, 10747340.
45. Rubio-Gayosso I, Platts SH, Duling BR. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol 2006, 290:H2247-2256.
46. Valensi P, Behar A, Andre P, Wiernsperger N, Attali JR. The effects of metformin on the capillary permeability to albumin in women patients with cyclic edema. Angiology 1995, 46:401-408. 10.1177/000331979504600506, 7741323.
47. Erdmann E. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. Int J Cardiol 2006, 107:147-153. 10.1016/j.ijcard.2005.03.053, 15975669.
48. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Eur J Physiol 2007, 454:345-359.
49. Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Carv Res 2010, 87:300-310.
50. Bellin C, de Wiza DH, Wiernsperger NF, Rosen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res 2006, 38:732-739. 10.1055/s-2006-955084, 17111300.
51. Rosen P, Wiernsperger NF. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diab/Metab Res Rev 2006, 22:323-330.
52. Ahmad S, Shahab U, Baig MH, Khan MS, Srivastava AK, Saeed M, Moinuddin. Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PloS one 2013, 8:e72128. 10.1371/journal.pone.0072128, 3762829, 24023728.
53. Faure P, Wiernsperger N, Polge C, Favier A, Halimi S. Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci 2008, 114:251-256. 10.1042/CS20070276, 17922677.